C
Cellino Biotech
Making personalized, autologous cell therapies accessible for patients
About Cellino Biotech
Cellino Biotech is a biotechnology company focused on the development of an autonomous biomanufacturing platform for personalized cell therapies. The company's proprietary platform integrates artificial intelligence, label-free imaging, and high-speed laser editing to automate and scale the production of induced pluripotent stem cells (iPSCs).
The primary goal is to overcome the significant manufacturing bottlenecks that currently limit the accessibility and affordability of autologous cell therapies, which are therapies derived from a patient's own cells. By automating the removal of unwanted cells and ensuring the quality of the final cell product, Cellino aims to reduce the cost and time associated with producing these personalized treatments.
The company's business model appears to be centered on collaborations and partnerships with other biotechnology and pharmaceutical firms. A notable example is its partnership with Karis Bio to develop an autologous iPSC-derived therapy for cardiovascular disease. This B2B approach allows Cellino to leverage its technology platform across various therapeutic areas. The company operates in the regenerative medicine and cell therapy markets, a sector with high growth potential.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Cambridge, United States
- Employees
- 108
- Open positions
- None listed
- Dealroom signal
- 62.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Synthetic Biology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Sep 2024 | $25M | — | US Department of Health and Human Services | ↗ |
| SERIES AOther financing | Jan 2022 | $80M | $320M | Felicis · 8VC · Humboldt Fund · Khosla Ventures | ↗ |
Growth signals
Latest recorded traffic for Cellino Biotech is 4.5K monthly website visits, up 0% over the last three months. Cellino Biotech's team declined 6.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
SPIE Photonics West
MassChallenge
Khosla Ventures
The Engine
8VC
Humboldt Fund
US Department of Health and Human Services
Series A2 investors entered at this stage
Leaps by Bayer
Felicis
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cellino Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cellino Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.